Dermatological Drugs - Netherlands

Netherlands

The Netherlands is projected to see a revenue of €100.20m in the Dermatological Drugs market by 2024.
It is expected to experience an annual growth rate (CAGR 2024-2029) of 5.75%, leading to a market volume of €132.50m by 2029.
When compared globally, United States is anticipated to generate the highest revenue of €10,820.00m in 2024.
The Netherlands is experiencing a surge in demand for dermatological drugs due to its high prevalence of skin diseases.

Key regions: United Kingdom, Canada, Japan, Europe, China

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Netherlands, known for its iconic windmills and tulip fields, is also a significant player in the global pharmaceutical market. One of the key segments in the pharmaceutical industry is the dermatological drugs market.

Customer preferences: Dermatological drugs are used to treat various skin conditions such as acne, psoriasis, eczema, and rosacea. The demand for these drugs in the Netherlands is driven by several factors, including the increasing prevalence of skin diseases, the growing aging population, and the rising awareness of skincare. Additionally, the high disposable income of the Dutch population enables them to spend more on skincare products.

Trends in the market: The dermatological drugs market in the Netherlands is witnessing several trends. One of the significant trends is the growing demand for biologic drugs. Biologic drugs are a new class of drugs that are derived from living organisms and are used to treat various skin diseases. These drugs have gained popularity in recent years due to their effectiveness and fewer side effects. Another trend is the increasing use of topical drugs. Topical drugs are applied directly to the skin and are used to treat mild to moderate skin conditions. The use of topical drugs is growing as they are easy to use, have fewer side effects, and are less expensive than other forms of treatment.

Local special circumstances: The Netherlands has a well-established healthcare system, which provides universal coverage to its citizens. The government plays a significant role in regulating the pharmaceutical industry and ensuring that drugs are safe, effective, and affordable. Additionally, the Netherlands is home to several leading pharmaceutical companies, including Janssen Pharmaceuticals, Pfizer, and Novartis, which are actively involved in the development and production of dermatological drugs.

Underlying macroeconomic factors: The dermatological drugs market in the Netherlands is influenced by several macroeconomic factors. One of the key factors is the aging population. As the population ages, the incidence of skin diseases increases, leading to a higher demand for dermatological drugs. Another factor is the growing awareness of skincare. The Dutch population is becoming increasingly conscious of the importance of skincare, which is driving the demand for dermatological drugs. Additionally, the high disposable income of the Dutch population enables them to spend more on skincare products, which is further fueling the growth of the dermatological drugs market. In conclusion, the dermatological drugs market in the Netherlands is witnessing several trends, including the growing demand for biologic drugs and the increasing use of topical drugs. The market is driven by several factors, including the aging population, the rising awareness of skincare, and the high disposable income of the Dutch population. The Netherlands' well-established healthcare system and the presence of leading pharmaceutical companies further support the growth of the dermatological drugs market in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.